Search results
Showing 1 to 9 of 9 results for medroxyprogesterone acetate
In development [GID-TA11461] Expected publication date: 16 April 2025
In development [GID-TA11503] Expected publication date: 10 September 2025
In development [GID-TA11340] Expected publication date: 21 May 2025
This guideline covers advice on the diagnosis and management of tension-type headache, migraine (including migraine with aura and menstrual-related migraine), cluster headache and medication overuse headache in young people (aged 12 years and older) and adults. It aims to improve the recognition and management of headaches, with more targeted treatment to improve the quality of life for people with headaches, and to reduce unnecessary investigations.
Mental health of adults in contact with the criminal justice system (NG66)
This guideline covers assessing, diagnosing and managing mental health problems in adults (aged 18 and over) who are in contact with the criminal justice system. It aims to improve mental health and wellbeing in this population by establishing principles for assessment and management, and promoting more coordinated care planning and service organisation across the criminal justice system.
limited evidence for pharmacological interventions (for example, medroxyprogesterone acetate) provides no clear evidence of benefit in...
This guideline covers care for women of any age (including girls and young women under 18) who request an abortion. It aims to improve the organisation of services and make them easier for women to access. Detailed recommendations on conducting abortions at different gestational stages are also included, to ensure that women get the safest and most effective care possible.
This guideline covers the diagnosis and management of prostate cancer in secondary care, including information on the best way to diagnose and identify different stages of the disease, and how to manage adverse effects of treatment. It also includes recommendations on follow-up in primary care for people diagnosed with prostate cancer.
This evidence summary has been replaced by the long-acting reversible contraception: implementation resource summary.